Coverage
-
August 11, 2015
The U.S. Food and Drug Administration and Amarin Pharmaceuticals Ireland Ltd. attacked efforts by Watson Laboratories Inc. to appeal a recent D.C. federal court decision on exclusivity for omega-3 drug Vascepa, arguing Monday that the company's proposed intervention is premature.
4 other articles on this case.
View all »